Why Immunogenicity Risk Assessment?

Understanding Immunogenicity in Biologic Development

What is Immunogenicity?

Immunogenicity is the ability of a therapeutic protein, or related impurities, to provoke an undesired immune response. This response may be driven by sequence characteristics, structural elements, post‑translational modifications, aggregation, formulation components, manufacturing changes, or patient‑specific factors. 

Why Does it Matter? 

Immune responses to biologics can reduce therapeutic efficacy, alter pharmacokinetics, or result in adverse clinical outcomes. These effects complicate dose selection, data interpretation, and long-term use. In some cases, immunogenicity issues emerge only after substantial clinical investment has already been made. 

Regulators therefore expect a structured, risk‑based approach to immunogenicity assessment that demonstrates scientific rationale, appropriate monitoring, and mitigation strategies across development. 

When Should Immunogenicity Be Assessed?

Immunogenicity assessment is most effective when it begins early, during candidate selections and lead optimization, and continues through preclinical development, clinical trials, and lifecycle management.  

Early assessment allows teams to identify inherent risks while there is still flexibility to refine sequence design or prioritize lower‑risk candidates. As development progresses, reassessment supports interpretation of emerging data and helps contextualize clinical findings. 

FDA Guidance:

EGuidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products

EClinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry

EANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry

EClinical Pharmacology Considerations for Peptide Drug Products

ERoadmap to Reducing Animal Testing in Preclinical Safety Studies 

EMA Guidance:

EGuideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins

Early insight offers options: Once a therapeutic reaches the clinic, opportunities to reduce immunogenicity are more limited.  

How and When Does Immunogenicity Data Help? 

Immunogenicity data provides decision‑enabling insight when generated in the right sequence and applied in context. 

In silico assessment is the recommended first step, enabling rapid evaluation and benchmarking of one to many candidates. These sequence-based predictions help to identify regions with elevated potential for immune recognition, compare relative immunogenicity risk across candidate molecules, and help teams understand which sequence features may contribute to predicted responses. The resulting data supports early lead prioritization, candidate characterization and optimization, and more focused downstream testing before drug material is available for laboratory testing.  

In vitro assays are then applied selectively to further characterize and validate, particularly as candidates advance and development questions become more specific. These studies can help confirm predicted liabilities, evaluate the robustness and specificity of immune responses, and provide additional context around potential clinical relevance as development questions become more targeted. 

Together, this tiered approach supports informed decision-making while reducing unnecessary expenses or delays.  

5See how in silico insights and in vitro data work together across development stages

Applications of immunogenicity data for each phase of biologic development

Across the development lifecycle, immunogenicity data supports: 

  • Prioritization of lead candidates by identifying molecules with lower predicted immunogenic risk early in discovery  
  • Deselection or re-engineering of candidates with sequence regions associated with elevated immune recognition potential  
  • Detailed characterization of lead candidates to better understand the nature, magnitude, and potential drivers of immune responses  
  • Comparison of candidate variants, formulation changes, or manufacturing-related sequence modifications during optimization activities  
  • Development of tailored bioanalytical and clinical monitoring strategies based on the specific risk profile of a therapeutic program  
  • Support for regulatory documentation, including preparation of Immunogenicity Risk Assessment sections for IND submissions and Integrated Summaries of Immunogenicity for BLA or ANDA filingsÂ